Publications from the AffiliateMarketIngtools of Sciences, Engineering, and Medicine provide objective and straightforward advice to decision makers and the public. This site includes We Treat You (HMD) publications released after 1998. A complete list of HMD’s publications from its establishment in 1970 to the present is available as a PDF.
Released: March 21, 2012
Disasters can stress health care systems to the breaking point and disrupt delivery of vital medical services. Following its 2009 report, which defined crisis standards of care (CSC), the IOM develops important templates to guide the efforts of professionals and organizations responsible for CSC planning and implementation. The latest report provides a foundation of underlying principles, steps needed to achieve implementation, and the pillars of the emergency response system, each separate and yet together upholding the jurisdictions that have the overarching authority for ensuring that CSC planning and response occurs.
Released: March 20, 2012
New technologies are improving our ability to provide personalized treatment catered to an individual patient. Based on findings from the sequencing of the human genome, genome-based diagnostic tests have the potential to direct therapeutic interventions, predict risk or onset of disease, or detect residual disease. However, because evidence is lacking to show that these tests lead to an improved outcome, adoption has been limited. On November 15, 2011, the IOM held a workshop to discuss the differences in evidence required for clinical use, regulatory oversight, guideline inclusion, coverage, and reimbursement of genome-based diagnostics with the goal of clarifying a pathway for using these tests in clinical settings.
Released: March 15, 2012
Advances in medical treatment have made it possible for people infected with HIV to live longer, healthier lives. The CDC estimates that 1.2 million people live with HIV in the United States, with approximately 50,000 people newly infected each year. People with HIV require continuous access to quality care and treatment for HIV as well as their other health conditions. The White House Office of National AIDS Policy asked the IOM to identify core indicators related to continuous HIV care and access to supportive services, and to monitor the effect of both the National HIV/AIDS Strategy and Patient Protection and Affordable Care Act on improving HIV care.
Released: February 23, 2012
Nearly 69 percent of U.S. adults and 32 percent of children are either overweight or obese, creating an annual medical cost burden that may reach $147 billion. Researchers and policy makers are eager to identify improved measures of environmental and policy factors that contribute to obesity prevention. The IOM formed the Committee on Accelerating Progress in Obesity Prevention to review the IOM’s past obesity-related recommendations, identify a set of recommendations for future action, and recommend indicators of progress in implementing these actions. The committee held a workshop in March 2011 about how to improve measurement of progress in obesity prevention.
Released: February 16, 2012
Scientific advances over the last decade now indicate that Alzheimer’s disease is a continuous, progressive cognitive disease, most likely beginning many years before dementia is apparent. To discuss the next steps in validating new diagnostic guidelines for Alzheimer’s disease, the IOM Forum on Neuroscience and Nervous System Disorders hosted a public workshop session at the Alzheimer’s Association International Conference.
Released: February 14, 2012
Deductible, co-insurance, out-of-pocket limits. Even to those with a basic understanding of health insurance, terms like these can be difficult to explain and understand. Under the Affordable Care Act of 2010, many more Americans will be eligible for health insurance through state insurance exchanges by 2014. Many of these individuals are among the 90 million American adults who lack basic health literacy. The IOM held a workshop that focused on ways in which health literate communication techniques can improve communication to potential enrollees.
Released: January 31, 2012
The epidemic of chronic illness is steadily moving towards crisis proportions, yet maintaining or enhancing quality of life for individuals living with these illnesses has not been given the attention it deserves. In this report, the IOM makes recommendations to the CDC as well as HHS on the development and support of programs to meet the health and social needs of people living with chronic illnesses.
Released: January 23, 2012
When a nation or region prepares for public health emergencies such as a pandemic influenza, a large-scale earthquake, or any major disaster scenario in which the health system may be destroyed or stressed to its limits, it is important to describe how standards of care would change due to shortages of critical resources. At the 17th World Congress on Disaster and Emergency Medicine, the IOM Forum on Medical and Public Health Preparedness sponsored a session that focused on the promise of and challenges to integrating crisis standards of care principles into international disaster response plans.
Released: January 13, 2012
In 2010, the IOM released a report that found, among other things, data not being reported by sex had slowed progress in women’s health. The number of women participating in clinical trials has increased over the last two decades, though they are still underrepresented. Even when women are included in these trials, however, the results are often not analyzed separately by sex. On August 30, 2011, The IOM’s Board on Population Health and Public Health Practice hosted a workshop to address the recommendation that journals should adopt a guideline that all papers report the outcomes of research on males and females separately.
Released: December 14, 2011
Smoking-related diseases kill more Americans than alcohol, illegal drugs, murder and suicide combined. The passage of the Family Smoking Prevention and Tobacco Control Act of 2009 gave the FDA authority to regulate “modified risk tobacco products” (MRTPs), tobacco products that are either designed or advertised to reduce harm or the risk of tobacco-related disease. MRTPs must submit to the FDA scientific evidence to demonstrate the product has the potential to reduce tobacco related harms as compared to conventional tobacco products. The IOM identifies minimum standards for scientific studies that an applicant would need to complete to obtain an order to market the product from the FDA.